Clinical trials: Lymphoma, Non-Hodgkin
Diffuse Large B-Cell Lymphoma (DLBCL), Follicular NHL Grade 3b
A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13
This is a randomized, open label, phase III study to evaluate the ability of rituximab maintenance therapy to prolong event-free survival in aggressive NHL.
- Trial name
- NCT00400478
- Testing
- Rituximab
- Where
- 131 sites in Australia, Austria and 24 more
- Volunteers
- 683 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
The purpose of this study is to evaluate pidilizumab and its effect, bad and/or good, on the immune system in relation to its ability to fight cancer cells.
- Trial name
- NCT02530125
- Testing
- Laboratory Biomarker Analysis, Pidilizumab
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Northwestern University
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
- Trial name
- NCT03299738
- Testing
- C-CAR011
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai AbelZeta Ltd.
Lymphoma, Follicular
Autologous Vaccine for Follicular Lymphoma
This phase I study will evaluate the safety and tolerability of an autologous idiotype vaccine manufactured by magnICON technology for patients with relapsed follicular lymphoma who are in complete or partial remission following…
- Trial name
- NCT01022255
- Testing
- Autologous FL vaccine
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Icon Genetics GmbH
Lymphoma
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- ManteauRiBVD (NCT00740415)
- Testing
- rituximab, bortezomib, dexamethasone
- Where
- France
- Volunteers
- 39 people
- Sponsor
- French Innovative Leukemia Organisation
Extranodal NK/T-cell Lymphoma
Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma
This is a multicenter, randomized, Phase 2 clinical trial designed to evaluate the efficacy and safety of golidocitinib combined with the P-GemOx (pegaspargase + gemcitabine + oxaliplatin) regimen plus PD-1 inhibitor, compared…
- Trial name
- NCT07385989
- Testing
- Golidocitinib in combination with P-GEMOX and PD-1 inhibitor, PD-1 inhibitor in combination with P-GEMOX
- Volunteers
- 40 people
- Sponsor
- WEI XU
Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma
Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HL
In case of relapsed or refractory ALK-negative ALCL patients, high-dosage chemotherapy/ stem cell transplantation is a universal salvage option for patients with sensitivity to anti-cancer treatment and a relatively successful…
- Trial name
- BRAVO (NCT03766516)
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Samsung Medical Center
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This clinical trial studies the use of reduced intensity chemotherapy and radiation therapy before donor stem cell transplant in treating patients with hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Aplastic Anemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT02566304
- Testing
- Fludarabine, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency
This randomized pilot early phase I trial studies how well cholecalciferol works in treating patients with newly diagnosed non-Hodgkin lymphoma or chronic lymphocytic leukemia with low levels of vitamin D (vitamin D deficiency).
- Conditions
- Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Untreated Chronic Lymphocytic Leukemia, Vitamin D Deficiency
- Trial name
- NCT02553447
- Testing
- Cholecalciferol, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- University of Nebraska
Follicular Lymphoma, Chronic Lymphocytic Leukemia
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
This study will evaluate the safety and tolerability of GS-9901 monotherapy in adults with follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL).
- Conditions
- Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT02258555
- Testing
- GS-9901
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gilead Sciences
Lymphoma
Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
RATIONALE: Giving chemotherapy and monoclonal antibody therapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00720447
- Testing
- alemtuzumab, donor lymphocytes, carmustine
- Volunteers
- 25 people
- Sponsor
- Cancer Research UK
Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Adult patients with r/r acute lymphoblastic leukemia (ALL) (stratum I), r/r Non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) or mantle…
- Conditions
- Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03676504
- Testing
- CD19.CAR T Cells, Fludarabine, Cyclophosphamide
- Where
- 2 sites in Germany
- Volunteers
- 68 people
- Sponsor
- University Hospital Heidelberg
B Cell Leukemia, B Cell Lymphoma
A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
Autologous T cells engineered to express chimeric antigen receptors (CARs) against leukemia antigens such as CD19 on B cells have shown promising results for the treatment of relapsed or refractory B-cell malignancies.
- Trial name
- NCT03166878
- Testing
- UCART019
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese PLA General Hospital
Peripheral T-Cell Lymphoma
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
This is a prospective single-arm, multicenter, phase Ib clinical trial of PI3Kδ inhibitor Parsaclisib combined with chidamide for the treatment of relapsed/refractory peripheral T-cell lymphoma.
- Trial name
- NCT05083208
- Testing
- Parsaclisib, Chidamide
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Henan Cancer Hospital
Advanced Cancer, Metastatic Cancer
A Study of LY3023414 in Participants With Advanced Cancer
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer
- Trial name
- NCT01655225
- Testing
- LY3023414, Midazolam, Fulvestrant
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 156 people
- Sponsor
- Eli Lilly and Company
Follicular Lymphoma
A Phase II Trial of Intermediate Radiation Dose For Lymphoma
The purpose of this study is to determine the optimal radiation dose fractionation regimen for low grade follicular lymphoma. It is hypothesized that the complete response rate with the use of 12 Gy in 6 daily fractions is 80%…
- Trial name
- NCT05284825
- Testing
- 12 Gy in 6 daily fractions
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
This is a Phase I, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia, Phase Ib). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated…
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT04018248
- Testing
- BR101801 (Phase Ia), BR101801 (Phase Ib)
- Where
- 9 sites in United States, South Korea
- Volunteers
- 26 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
This pilot trial studies different high-dose chemotherapy regimens with or without total-body irradiation (TBI) to compare how well they work when given before autologous stem cell transplant (ASCT) in treating patients with…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT00536601
- Testing
- etoposide, cyclophosphamide, carmustine
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Roswell Park Cancer Institute
Multiple Myeloma, Non-Hodgkin Lymphoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
- Trial name
- NCT04045028
- Testing
- Tiragolumab, Daratumumab/rHuPH20, Rituximab
- Where
- 14 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Genentech, Inc.
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of panobinostat and everolimus when given together and to see how well they work in treating patients with multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00918333
- Testing
- panobinostat, everolimus, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.